Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Minerva Biotechnologies
Minerva's MUC1* Inhibitors Reverse Resistance to Chemotherapy
May 26th, 2009
Minerva Biotechnologies, a leading cancer and stem cell development company, announced a major breakthrough in the treatment of cancers. In an article published this month in the Journal of Breast Cancer Research and Treatment, “MUC1* is a Determinant of Trastuzumab (Herceptin) Resistance in Breast Cancer Cells” Minerva researchers reported that tumor cells that had grown resistant to anti-cancer drugs do so by over-expressing a growth factor receptor that they named MUC1*. Researchers reversed the drug resistance by treating the cancer cells with the original drug plus one of Minerva’s...
Source: Cancer Weekly (2009-05-26)
|
